To Study the Efficacy of Directly Acting Antivirals In Patients of Hepatitis C Infection who are On Dialysis.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Chronic Kideny Disease Patients on Hemodialysis With Hepatitis C infectionHealth Condition 2: N186- End stage renal disease
- Registration Number
- CTRI/2018/06/014408
- Lead Sponsor
- INDRAPRASTHA APOLLO HOSPITA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 34
Inclusion Criteria
Patients with Chronic Kidney Disease on Hemodialysis with
concomitant Hepatitis C infection with or without compensated Liver Cirrhosis
Exclusion Criteria
Patients with Decompensated Liver Cirrhosis
2) Patients with Significant alcohol intake history
3) Concomitant Chronic Hepatitis B infection or HIV infection
4) NASH
5) Pregnancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients achieving the Sustained Virological response at 12 <br/ ><br>weeks post therapyTimepoint: 12 weeks post therapy
- Secondary Outcome Measures
Name Time Method a) To find out percentage of patients achieving the Virological response at end of <br/ ><br>therapy <br/ ><br>b) To find the incidence of adverse events of directly acting antivirals in patients with <br/ ><br>Chronic kidney disease on HaemodialysisTimepoint: At end of 12 week of therapy